BidaskClub upgraded shares of CymaBay Therapeutics (NASDAQ:CBAY) from a sell rating to a hold rating in a report published on Thursday.

Several other research firms also recently weighed in on CBAY. ValuEngine upgraded CymaBay Therapeutics from a buy rating to a strong-buy rating in a research note on Wednesday, May 2nd. Oppenheimer set a $18.00 price target on CymaBay Therapeutics and gave the stock a buy rating in a research note on Wednesday, April 11th. Leerink Swann upped their price target on CymaBay Therapeutics from $16.00 to $20.00 and gave the stock an outperform rating in a research note on Wednesday, April 11th. HC Wainwright restated a buy rating and issued a $23.00 price target (up previously from $21.00) on shares of CymaBay Therapeutics in a research note on Wednesday, June 6th. Finally, Zacks Investment Research downgraded CymaBay Therapeutics from a hold rating to a sell rating in a research note on Tuesday, July 10th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $21.88.

Shares of CymaBay Therapeutics traded up $0.45, hitting $12.09, during midday trading on Thursday, Marketbeat.com reports. The company had a trading volume of 1,268,105 shares, compared to its average volume of 622,850. The company has a debt-to-equity ratio of 0.01, a quick ratio of 12.91 and a current ratio of 12.91. CymaBay Therapeutics has a 52-week low of $5.56 and a 52-week high of $15.59.

CymaBay Therapeutics (NASDAQ:CBAY) last posted its quarterly earnings results on Friday, August 10th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.04). research analysts anticipate that CymaBay Therapeutics will post -1.16 EPS for the current year.

In other CymaBay Therapeutics news, CEO Sujal Shah bought 5,000 shares of the business’s stock in a transaction on Friday, July 27th. The shares were acquired at an average cost of $10.90 per share, for a total transaction of $54,500.00. Following the purchase, the chief executive officer now owns 95,000 shares in the company, valued at approximately $1,035,500. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 4.50% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. DRW Securities LLC boosted its stake in CymaBay Therapeutics by 41.7% during the 1st quarter. DRW Securities LLC now owns 17,000 shares of the biopharmaceutical company’s stock valued at $221,000 after purchasing an additional 5,000 shares during the last quarter. LVM Capital Management Ltd. MI boosted its stake in CymaBay Therapeutics by 23.8% during the 2nd quarter. LVM Capital Management Ltd. MI now owns 26,000 shares of the biopharmaceutical company’s stock valued at $349,000 after purchasing an additional 5,000 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in CymaBay Therapeutics by 63.4% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 20,365 shares of the biopharmaceutical company’s stock valued at $265,000 after purchasing an additional 7,900 shares during the last quarter. Allianz Asset Management GmbH boosted its stake in CymaBay Therapeutics by 6.7% during the 1st quarter. Allianz Asset Management GmbH now owns 126,958 shares of the biopharmaceutical company’s stock valued at $1,649,000 after purchasing an additional 7,949 shares during the last quarter. Finally, Hillsdale Investment Management Inc. purchased a new stake in CymaBay Therapeutics during the 1st quarter valued at $104,000. Institutional investors and hedge funds own 82.24% of the company’s stock.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Further Reading: Are Wall Street analysts’ stock ratings worth following?

Analyst Recommendations for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.